PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-12-09

Date Title Company
09-Dec-2025 SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS Businesswire
09-Dec-2025 Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada Businesswire
09-Dec-2025 Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma Businesswire
09-Dec-2025 Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET Businesswire
09-Dec-2025 Campo Indictment Exposes DEA Rotted From Within - While Medical Cannabis Research and Patients Wait Seven Years ACCESS Newswire
09-Dec-2025 Most Americans With OCD Never Receive Effective Treatment, Landmark Study Finds ACCESS Newswire
09-Dec-2025 OPEN Health Welcomes Diala Habib to Drive a New Era of Human-Centric Engagement Connecting HCPs, Patients, and Purpose OPEN Health
09-Dec-2025 2026 Regulatory Crossfire: New Outlook Survey Reveals Health IT Rules Reshaping U.S. Care Delivery ACCESS Newswire
09-Dec-2025 World’s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis Businesswire
09-Dec-2025 A glass of red wine this Christmas could be good for you, says expert. It’s ‘The French Paradox’! Sinclair Method UK
09-Dec-2025 Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology Oncoinvent
09-Dec-2025 Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS) Newron
09-Dec-2025 PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis PureTech
09-Dec-2025 Poolbeg Pharma plc - POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme Poolbeg Pharma
09-Dec-2025 SeaBeLife enters into joint development agreement with Unither Pharmaceuticals to formulate and produce ophthalmic drug candidate SeaBeLife
09-Dec-2025 Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer Pan Cancer T
09-Dec-2025 RYBREVANT®▼(amivantamab) in combination with carboplatin and pemetrexed is accepted for use within NHS Scotland as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations Johnson & Johnson
09-Dec-2025 Senzime secures major TetraGraph order from leading UK NHS hospital system Senzime
09-Dec-2025 Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome Fibrocor Therapeutics
09-Dec-2025 Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma J&J